COMMUNIQUÉS West-GlobeNewswire

Catheter Precision, Inc. Reports Results of Operations for Second Quarter 2025
11/08/2025
Revenue Increased 128% Year Over Year and 48% Sequentially FORT MILL, S.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing [...]
IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed
11/08/2025
Patients treated with Cylembio (imsapepimut and etimupepimut, adjuvanted) plus pembrolizumab achieved improvement in progression free survival (PFS) compared to patients treated with pembrolizumab monotherapy, HR=0.77 ( [...]
Protara Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update
11/08/2025
Presentation of interim analysis from approximately 25 six-month evaluable BCG-Unresponsive patients in the ongoing ADVANCED-2 trial expected at a medical conference in 1Q 2026 Dosing of first patient in THRIVE-3 [...]
ProPhase Labs Inc. to Present Second Quarter 2025 Financial Results on August 13, 2025
11/08/2025
UNIONDALE, NY, Aug. 11, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”), a next generation biotech, genomics and consumer products company, announced today that they will be [...]
Inspire Medical Systems, Inc. Board Authorizes Share Repurchase Program
11/08/2025
MINNEAPOLIS, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire, or the company), a medical technology company focused on the development and commercialization of innovative, minimally [...]
ArriVent BioPharma Reports Second Quarter 2025 Financial Results
11/08/2025
Positive interim Phase 1b update underscores firmonertinib’s potential in EGFR PACC mutant NSCLC; global pivotal Phase 3 ALPACCA study expected to enroll first patient in 2H 2025 Dosed the first patient in the Phase 1 [...]
Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference
11/08/2025
CONSHOHOCKEN, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the Canaccord Genuity 45 th Annual Growth Conference on Tuesday, [...]
4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
11/08/2025
4D-150 Phase 3 program in wet AMD advancing ahead of plan, with expected 4FRONT-1 data readout accelerated to H1 2027 from H2 2027 and 4FRONT-2 initiated ahead of schedule Presented positive 60-week results from 4D-150 [...]
vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin
11/08/2025
HIGH POINT, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin , a potential first-in-class oral adjunctive [...]
Theriva™ Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results
11/08/2025
- Released positive topline data from the VIRAGE Phase 2b study of VCN-01 (zabilugene almadenorepvec); expanded data to be presented at the European Society for Medical Oncology (ESMO) 2025 Congress in October - - VCN- [...]
Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025
11/08/2025
COPENHAGEN, Denmark, August 11, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its [...]
Full Alliance Group’s Qubitera Holdings Expands Quant Blockchain Healthcare Development Roadmap
11/08/2025
Qubitera Holdings Charts Mid-2027 Global Launch for Quantum-Safe EHR/EMR Platform TAMPA, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Full Alliance Group, Inc. (OTC: FAGI) announced today that its subsidiary, Qubitera [...]
Safety Shot Announces Strategic Alliance with Bonk Founding Contributors, Initiating BONK Treasury Strategy
11/08/2025
Company to Receive $25 Million in BONK Tokens from Founding Contributors of BONK, Establishing a New Model for Public Company Participation in DeFi SCOTTSDALE, AZ, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. ( [...]
Veru Announces Selection of Novel Modified Release Oral Enobosarm Formulation for Chronic Weight Loss Management Following Pharmacokinetic Clinical Study
11/08/2025
MIAMI, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory [...]
Oragenics Q2 2025 Shareholder Update
11/08/2025
Advancing Brain-First Recovery Platform Toward Clinical Milestones Pioneering Intranasal Therapeutics for Concussion SARASOTA, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a pioneering [...]
XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics
11/08/2025
- Turnstone Stockholders Received $0.34 Per Share in Cash Plus Contingent Value Right - EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) (“XOMA Royalty” or the “Company”), a [...]
FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy
11/08/2025
NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development [...]
Windtree Announces Istaroxime has been Chosen for a Plenary Session Presentation at the Heart Failure Society of America 2025
11/08/2025
Presentation will be the interim data from the Phase 2 study of istaroxime in SEISMiC C - Cardiogenic Shock SCAI Stage C Cardiogenic shock SCAI Stage C has an in hospital mortality rate of 20-30% Istaroxime interim data [...]
Artelo Biosciences Receives Notice of Allowance from European Patent Office for the Patent Claims for the Intended Commercial Formulation of ART27.13
11/08/2025
Extends Patent Protection Through December 2041 ART27.13 is Currently under Evaluation in a Phase 2 Study for the Treatment of Cancer-Related Anorexia SOLANA BEACH, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Artelo [...]

Pages